LMTK2: Potential Drug Target Or Biomarker (G22853)

LMTK2: Potential Drug Target Or Biomarker

LMTK2 (Low Molecular Weight Tissue Kallikrein-like) is a protein that is expressed in various tissues throughout the body. It is a member of the kallikrein family, which includes several other proteins that play important roles in the regulation of cardiovascular and other physiological processes . LMTK2 has been shown to be involved in several different biological processes, including the regulation of blood clotting, inflammation, and cell signaling. As a result, LMTK2 has generated a lot of interest as a potential drug target or biomarker.

One of the key functions of LMTK2 is its role in blood clotting. LMTK2 is a potent inhibitor of platelet aggregation, which is a key event in the formation of blood clots. Blood clots can be a serious health problem, as they can block blood flow to the body's tissues and organs, leading to hypoxia, pain, and other serious complications. LMTK2 has been shown to be particularly effective in inhibiting the formation of platelet aggregations in areas of the body that are rich in platelets, such as the lungs, heart, and brain.

In addition to its role in blood clotting, LMTK2 has also been shown to be involved in the regulation of inflammation. Inflammation is a natural response of the immune system, but when inflammation becomes chronic or uncontrolled, it can lead to a range of diseases, including heart disease, cancer, and autoimmune disorders. LMTK2 has been shown to be involved in the regulation of inflammation by controlling the activity of immune cells called T cells. T cells are a critical part of the immune system, and they play a key role in detecting and responding to the presence of foreign or abnormal cells in the body. LMTK2 has been shown to regulate the activity of T cells in a way that promotes healthy immune responses, while preventing excessive or uncontrolled inflammation.

Another function of LMTK2 is its role in cell signaling. Signal transduction is a critical process in many different biological processes, including cell signaling. LMTK2 is involved in signal transduction by regulating the activity of a protein called FAK. FAK is a protein that is involved in many different processes in the body, including cell signaling, adhesion, and migration. LMTK2 has been shown to regulate the activity of FAK in a way that promotes healthy cell signaling, while preventing excessive or uncontrolled signaling.

LMTK2 has also been shown to be involved in the regulation of cell proliferation. Cell proliferation is an essential process for the growth and development of all living organisms, and it is also a key factor in the development of many diseases, including cancer. LMTK2 has has been shown to regulate cell proliferation in a way that promotes healthy cell growth and division, while preventing excessive or uncontrolled cell proliferation.

In conclusion, LMTK2 is a protein that is expressed in various tissues throughout the body and is involved in several different biological processes, including blood clotting, inflammation, and cell signaling. As a result, LMTK2 has generated a lot of interest as a potential drug target or biomarker. Further research is needed to fully understand the role of LMTK2 in these processes and to develop safe and effective treatments for LMTK2-related diseases.

Protein Name: Lemur Tyrosine Kinase 2

Functions: Phosphorylates PPP1C, phosphorylase b and CFTR

The "LMTK2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LMTK2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

LMTK3 | LMX1A | LMX1B | LMX1B-DT | LNC-LBCS | LNCAROD | LNCARSR | LNCATV | LNCNEF | LNCOC1 | LNCOG | LNCPRESS1 | LNCRI | LNCRNA-ATB | LNCRNA-IUR | LNCTAM34A | LNP1 | LNPEP | LNPK | LNX1 | LNX1-AS1 | LNX2 | LOC100127946 | LOC100127955 | LOC100128002 | LOC100128028 | LOC100128050 | LOC100128059 | LOC100128079 | LOC100128093 | LOC100128164 | LOC100128242 | LOC100128288 | LOC100128317 | LOC100128361 | LOC100128398 | LOC100128494 | LOC100128593 | LOC100128770 | LOC100128966 | LOC100128988 | LOC100129034 | LOC100129098 | LOC100129148 | LOC100129175 | LOC100129203 | LOC100129215 | LOC100129316 | LOC100129381 | LOC100129434 | LOC100129455 | LOC100129534 | LOC100129603 | LOC100129697 | LOC100130000 | LOC100130207 | LOC100130285 | LOC100130298 | LOC100130331 | LOC100130452 | LOC100130463 | LOC100130548 | LOC100130587 | LOC100130691 | LOC100130698 | LOC100130744 | LOC100130748 | LOC100130872 | LOC100130899 | LOC100130938 | LOC100130987 | LOC100130992 | LOC100131096 | LOC100131107 | LOC100131257 | LOC100131289 | LOC100131372 | LOC100131496 | LOC100131532 | LOC100131626 | LOC100131635 | LOC100131859 | LOC100131877 | LOC100131943 | LOC100132004 | LOC100132062 | LOC100132077 | LOC100132078 | LOC100132249 | LOC100132287 | LOC100132356 | LOC100132609 | LOC100132626 | LOC100132651 | LOC100132686 | LOC100132741 | LOC100132781 | LOC100132797 | LOC100133077 | LOC100133165